Cargando…

LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity

Inadequate levels of serum total 25-hydroxyvitamin D (25D) in chronic kidney disease (CKD) are associated with an increased risk of secondary hyperparathyroidism (SHPT). Serum 25D can be difficult to raise sufficiently with vitamin D supplements (cholecalciferol or ergocalciferol) to effectively low...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strugnell, Stephen A, Ashfaq, Akhtar, Bishop, Charles W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Bone & Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628980/ http://dx.doi.org/10.1210/jendso/bvac150.312

Ejemplares similares

LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022)

LBSAT230 Daily Variation In Serum Calcifediol In Japanese And Non-japanese Adults
por: Ashfaq, Akhtar, et al.
Publicado: (2022)

LBSAT145 Localizing The "Difficult" Parathyroid Tumor
por: Graf, Akua, et al.
Publicado: (2022)

LBSAT127 An Underrecognized Entity: Hypercalcemia Induced PRES
por: Sari, Esra, et al.
Publicado: (2022)

LBSAT141 Bone Health In Patients With Adrenal Disorders
por: Dogra, Prerna, et al.
Publicado: (2022)

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

LBSAT130 Hypercalcemia In Pregnancy Due To CYP24A1 Mutation
por: Agu, Chinyere, et al.
Publicado: (2022)

LBSAT308 A Tale Of Two Endocrinopathies: Hyperthyroidism And Hypophysitis In A Case of Metastatic Melanoma
por: Loughner, Chelsea L, et al.
Publicado: (2022)

LBSAT140 Mortality Risk Following Atypical Femoral Fracture: A Systematic Review And Meta-analysis
por: Charroenngam, Nipith, et al.
Publicado: (2022)

LBSAT144 Single-center Experience With Hyperparathyroidism-jaw Tumor Syndrome - Where Do We Stand?
por: Tora, Rana S, et al.
Publicado: (2022)

LBSAT139 Osteoporosis Screening In Men As Per Endocrine Society Clinical Practice Guidelines: A Cross-sectional Study
por: Pradeep, Pallavi, et al.
Publicado: (2022)

Characteristics of Serum Ratios of 1,25-Dihydroxyvitamin D to 25-Hydroxyvitamin D for Assessment of Bone Metabolism
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

LBSAT142 Discovery And Characterization Of A Potent And Orally Bioavailable Parathyroid Hormone Receptor Type-1 (PTHR1) Antagonist For The Treatment Of Hypercalcemia
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2022)

Lack of Association Between 25-Hydroxyvitamin D Level and Outcomes in Hospitalized Indian Patients With COVID-19
por: Jevalikar, Ganesh, et al.
Publicado: (2021)

A Comparison of Free and Total 25-hydroxyvitamin D Levels as Functional Indicators of Bone Health in Healthy Children
por: Heo, You Joung, et al.
Publicado: (2021)

SAT229 Symptomatic Hypocalcemia In The Setting Of Crohn’s Disease With Severe Hypomagnesemia
por: Cuan, Katherine, et al.
Publicado: (2023)

Oleanolic Acid Modulates 25-Hydroxyvitamin D(3) 1-alpha-hydroxylase in Osteoblasts and Human Mesenchymal Stem Cells
por: Yu, Wen-Xuan, et al.
Publicado: (2021)

ODP096 Hypercalcemia Secondary to Vitamin D Supplementation with Normal 25-Hydroxyvitamin D Level in an Elderly Female - Case Report
por: Arora, Gunjan, et al.
Publicado: (2022)

LBODP016 Lithocholic Acid Induced 25-hydroxyvitamin D-1alpha Hydroxylase (cyp27b1) Expression And Activities In Vitro And In Vivo
por: Lam, Chung Yan, et al.
Publicado: (2022)

SAT-514 The Decrease in Serum Parathyroid Hormone on Vitamin D Treatment Is Similar When Comparing Increases in Serum Free or Total 25 Hydroxyvitamin D in White and Black Women
por: Smith, Lynette, et al.
Publicado: (2019)

MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Biomechanical Computed Tomography Captures Older Men at High Risk of Hip Fracture Despite Low Fracture Risk Calculation by FRAX
por: Fu, Polly, et al.
Publicado: (2021)

SUN-351 Sex Is a Strong Variable in the Mineral Metabolism Defects and Endocrine Dysfunction Associated with the Murine Adenine Diet Model of Chronic Kidney Disease (CKD)
por: Liesen, Michael P, et al.
Publicado: (2020)

MON-374 Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology
por: Menon, Sruthi, et al.
Publicado: (2020)

MON-LB74 The Problem of Measuring 1,25(OH)2 Vitamin D in Patients With High Levels of 25(OH) Vitamin D
por: Vieira, Jose Gilberto, et al.
Publicado: (2020)

Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
por: Santos, Lívia Marcela, et al.
Publicado: (2021)

SAT-356 Reversible Suppression of Serum 1,25-Dihydroxyvitamin D in Williams Syndrome
por: Torchinsky, Michael Yuri, et al.
Publicado: (2020)

SAT246 Ectopic (Penile) Calcification in 1, 25 Vitamin D Induced Hypercalcemia
por: Berquist, John, et al.
Publicado: (2023)

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)

MON-388 Total and Free 1,25dihydroxyvitamin D Levels in Postmenopausal Patients with Primary Hyperparathyroidism
por: Meng, Lingqiong, et al.
Publicado: (2020)

1-25OH(2)D Mediated Hypercalcemia Secondary to DISR From Immune Checkpoint Inhibitors
por: Disanti, Domenic, et al.
Publicado: (2021)

Appropriate Cutoff for 25OHD Levels in the Diagnosis of Normocalcemic Primary Hyperparathyroidism (NPHPT): A Systematic Review
por: Yedla, Niharika, et al.
Publicado: (2021)

SAT240 Recurrent Hypercalcemia Due To 1,25 Dihydroxy Vitamin D Elevation Of Unclear Etiology
por: Javvaji, Abhiram, et al.
Publicado: (2023)

SAT-531 Low 25-OH-Vitamin D Levels in Women Observed before Initiating Osteoporosis Therapy
por: Li, Christina, et al.
Publicado: (2019)

ODP079 BCG-Osis, a Rare Cause of 1,25 Hydroxy Vitamin D Mediated Hypercalcemia
por: Azim, Sidra, et al.
Publicado: (2022)

ODP109 PARATHYROID HORMONE AND 25 OH VITAMINA D IN PREGNANCY: DATA FROM AN ARGENTINEAN COHORT SUPPORTING SUPPLEMENTATION.
por: Torres, Marta Isabel, et al.
Publicado: (2022)

SAT257 Efficacy Of Oral Cinacalcet In Non-PTH Non-Malignant Hypercalcemia From Excess 1,25 Dihydroxyvitamin D
por: Mohan, Sneha, et al.
Publicado: (2023)

THU397 Homeostatic Regulation Of 1,25-dihydroxyvitamin D: Critical Role Of 24-hydroxylation (CYP24A1)
por: Yazdi, Zhinoosossadat Shahidzadeh, et al.
Publicado: (2023)

SAT176 Comparison Of Prevalence For Normocalcemic Primary Hyperparathyroidism (NPHPT) Using Different 25(OH)D Levels: A Systematic Review
por: Farooqi, Iqra N, et al.
Publicado: (2023)

Therapeutic Potentials of Dimeric (Cys25)PTH(1–34) Peptide for Osteoporosis and Fracture Healing of the Bones- Buy One, Get One Free
por: Park, Doori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_udh62vl06gfj92sj1rrk8v7ris